Rezolute Inc
NASDAQ:RZLT
Rezolute Inc
NASDAQ:RZLT
Price:
4.11 USD
1.99%
Market Closed
Updated:
Jun 4, 2024
Section:
Relative Value
There is not enough data to reliably calculate the relative value of RZLT.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
RZLT
Relative Value
Base Case
Not Available
Valuation Multiples
Multiples Across Competitors
RZLT Competitors Multiples
Rezolute Inc Competitors
Rezolute Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Rezolute Inc
NASDAQ:RZLT
|
164.9m USD | 0 | -2.8 | -1.4 | -1.4 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
282.9B USD | 5.2 | 47.5 | 13.4 | 20.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
164.9B USD | 5.6 | 43.8 | 18.5 | 30.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.4B USD | 11.9 | 30.2 | 25.4 | 26.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
109B USD | 8.3 | 28.3 | 22.9 | 25.4 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.9B AUD | 6.4 | 36.8 | 22.2 | 27.5 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
79B USD | 2.9 | 163.3 | 8.4 | 11 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
56.6B USD | 11 | -9.5 | -10.7 | -9.5 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
33.5B USD | 3.5 | 28.7 | 14.6 | 18.2 | |
| KR |
|
Celltrion Inc
KRX:068270
|
38.8T KRW | 16.7 | 98.7 | 49.7 | 83 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
